Corcept Therapeutics Inc (CORT)
| Market Cap | 12.93B+32.4% |
| Revenue (ttm) | n/a+16.0% |
| Net Income | n/a-58.7% |
| EPS | n/a-62.8% |
| Shares Out | 108.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 628,050 |
| Open | 118.60 |
| Previous Close | 119.57 |
| Day's Range | 117.23 - 122.00 |
| 52-Week Range | 28.66 - 126.38 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 125.33(+4.79%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CORT
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CORT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CORT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CORT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CORT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CORT Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Hypercortisolism Products | $208.58M | 81.43% |
| Lifyorli | $47.56M | 18.57% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CORT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CORT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CORT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $328.73M |
| VBVanguard Morningstar Small-Cap ETF | $237.98M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $136.59M |
| VXFVanguard Extended Market ETF | $125.83M |
| FBTFirst Trust NYSE Arca Biotechnology Index Fund | $117.82M |
| MDYState Street SPDR S&P MIDCAP 400 ETF Trust | $84.23M |
Estimated from each fund’s disclosed top holdings × AUM
CORT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CORT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score